Release
📈 Stocks
Genmab Reports 71% Risk Reduction in Phase 3 Ovarian Cancer Trial
(just now)
Genmab's Rina-S hit primary endpoints in a Phase 3 ovarian cancer trial, showing a 71% reduction in disease progression risk and paving…